A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes.

Trial Profile

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Omarigliptin (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
    • 26 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top